MMP-9 Antibody (YA285)
(Synonyms: MMP-9; GELB; MMP9; CLG4B)Based on 1 publication(s) in Google Scholar
MMP-9 Antibody (YA285) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MMP-9.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC, IF-Tissue
-
Reactivity :
Human, Rat
-
Formulation:
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Conjugation:
Non-conjugated
Publications Citing Use of MedChemExpress (MCE) MMP-9 Antibody (YA285)
More
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
IF-Tissue
IF-Tissue: Immunofluorescence-Tissue
|
|---|---|---|---|---|---|
| Dilution Ratio | 1:5000 | 1:50-1:200 | 1:200-1:1000 | 1:50-1:100 | 1:50-1:200 |
Product Details
MMP-9 Antibody (YA285) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MMP-9.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Rat
-
Observed Molecular WeightObserved band size: 92 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 78 kDa
Synthetic peptide corresponding to Human MMP9.AA range:71-120.
Endogenous
Protein A affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Front Chem
New molecular mechanisms of quercetin in improving recurrent spontaneous abortion based on in-depth network pharmacology and molecular docking. [Abstract]2024 Sep 4:12:1407667. PMID: 39296365
Verification Images
-
Western blot analysis of extracts from Rat lung tissue (lane2(20μg), Rat spleen tissue (lane3(20μg), Rat kidney tissue (lane4(20μg) and U-87MG (lane5(20μg) using MMP-9 Antibody (HY-P80425). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/5000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.
-
Immunohistochemical analysis of paraffin-embedded mouse spleen tissue using MMP-9 Antibody. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody at 1/100 dilution in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded mouse spleen tissue using MMP-9 Antibody. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody at 1/100 dilution in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunocytochemistry analysis of Hela cells labeling MMP-9 Antibody (HY-P80425) at 1/50 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with BSA for Immunol Staining for 10 min at room temperature. Cells were then incubated with MMP-9 Antibody (HY-P80425) at 1/50 dilution in BSA for Immunol Staining at 4 ℃ Overnight. AF488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
-
Immunocytochemistry analysis of Hela cells labeling MMP-9 Antibody (HY-P80425) at 1/200 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with BSA for Immunol Staining for 10 min at room temperature. Cells were then incubated with MMP-9 Antibody (HY-P80425) at 1/200 dilution in BSA for Immunol Staining at 4 ℃ Overnight. AF488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
Background
-
Function
MMP-9 (matrix metalloproteinase-9), also known as gelatinase B, is a zinc-dependent extracellular endopeptidase that mediates extracellular matrix remodeling through proteolytic cleavage of gelatin, type IV collagen, laminin, elastin, and additional matrix-associated substrates, thereby regulating tissue turnover, cell migration, and microenvironmental remodeling[1][2]. Mechanistically, MMP-9 is synthesized as an inactive proenzyme and becomes activated through proteolytic removal of its prodomain, enabling participation in inflammatory signaling, leukocyte trafficking, angiogenesis, and tissue repair processes[1][3]. MMP-9 also modulates biological activity of cytokines, chemokines, growth factors, and cell-surface signaling molecules, linking extracellular matrix degradation with immune and vascular responses[3][4]. In disease settings, dysregulated or persistent MMP-9 expression is associated with cancer progression, invasion, metastasis, vascular remodeling, neuroinflammatory disorders, and blood-brain barrier disruption, making MMP-9 a widely studied pathogenic mediator and biomarker candidate[3][5][6]. Compared with the closely related gelatinase MMP-2, MMP-9 displays distinct substrate preferences, inducible expression in inflammatory conditions, predominant storage in neutrophils, and primary inhibition by TIMP-1, whereas MMP-2 is generally constitutively expressed and preferentially regulated by TIMP-2[4]. Structural differences, including a unique loop region and distinct regulatory mechanisms, further support functional separation between the two gelatinases in physiological and pathological remodeling[2][4]. For experimental applications, MMP-9-selective inhibitors and neutralizing antibodies are widely used to investigate extracellular matrix remodeling, angiogenesis, inflammatory responses, and tumor progression, although achieving high selectivity remains a major challenge because of structural homology within the matrix metalloproteinase family[5][7].
-
Subcellular Localization
Secreted, extracellular space, extracellular matrix
-
Expression
Tissue_specificity:Protein levels were detected in neutrophils (PubMed: 7683678) . Produced by normal alveolar macrophages and granulocytes.
Induction:Activated by 4-aminophenylmercuric acetate and phorbol ester. Up-regulated by ARHGEF4, SPATA13 and APC via the JNK signaling pathway in colorectal tumor cells; (Microbial infection) Expression induced by M.bovis MPB83 (at protein level) (PubMed:20800577) -
Subunit
Exists as monomer or homodimer; disulfide-linked (PubMed:1281792, PubMed:7683678). Also exists as heterodimer with LCN2 (PubMed:1281792, PubMed:7683678). Macrophages and transformed cell lines produce only the monomeric form. Interacts with ECM1 (PubMed:16512877)
-
SwissProt ID
-
Synonyms
MMP-9; GELB; MMP9; CLG4B
-
Research Field
Cardiovascular
Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)
[1]. Mondal S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem. 2020 May 15;194:112260. [Content Brief]
[2]. Rashid ZA, et al. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment. Int J Mol Sci. 2023 Jul 28;24(15):12133. [Content Brief]
[3]. Li H, et al. Matrix Metalloproteinase-9 as an Important Contributor to the Pathophysiology of Depression. Front Neurol. 2022 Mar 18;13:861843. [Content Brief]
[4]. Nikolov A, et al. Role of Gelatinases MMP-2 and MMP-9 in Healthy and Complicated Pregnancy and Their Future Potential as Preeclampsia Biomarkers. Diagnostics (Basel). 2021 Mar 9;11(3):480. [Content Brief]
[5]. Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel). 2018 Sep 27;18(10):3249. doi: 10.3390/s18103249. PMID: 30262739; PMCID: PMC6211011. et al. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel). 2018 Sep 27;18(10):3249. [Content Brief]
[6]. Vandooren J, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013 May-Jun;48(3):222-72. [Content Brief]
[7]. Vandenbroucke RE, et al. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014 Dec;13(12):904-27. [Content Brief]